QUOTE AND NEWS
Cloud Computing  Mar 26  Comment 
TinderBox, the leading provider of sales workflow automation, today announces that it has raised $3 million in additional funding, the first venture-backed round for the company. The round was led by new investor, Allos Ventures, a Midwest-based...
Benzinga  Sep 6  Comment 
HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NASDAQ: SPPI)today announced the successful completion of the acquisition of Allos Therapeutics, Inc. (NasdaqGS: ALTH) (Allos), on September 5, 2012 through a...
Benzinga  Sep 5  Comment 
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) and Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that the offer period in connection with Spectrum's tender offer to purchase all of the outstanding shares of common...
StreetInsider.com  Aug 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/FTC+Clears+Spectrum%27s+%28SPPI%29+Acquisition+of+Allos+%28ALTH%29+Acquisition/7691614.html for the full story.
Benzinga  Aug 28  Comment 
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (Spectrum) and Allos Therapeutics, Inc. (NasdaqGS: ALTH) (Allos) today announced that the Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino...
Stock Blog Hub  Aug 21  Comment 
Recently, Allos Therapeutics Inc. (ALTH) and Spectrum Pharmaceuticals (SPPI) announced the extension of the offer period for the purchase of the entire outstanding common stock of the former. The offer period, which was set to expire on August 20,...
Benzinga  Jul 20  Comment 
Spectrum Pharmaceuticals (NASDAQ: SPPI) and Allos Therapeutics (NASDAQ: ALTH) announced Friday that Spectrum has provided an additional extension of the offer period in connection with its tender offer to purchase all of the outstanding shares of...
FierceBiotech  Jul 18  Comment 
Amag Pharmaceuticals ($AMAG) has received a dose of good news. Its second late-stage study of Feraheme as a treatment for iron deficiency anemia in a population of non-responders hit both primary endpoints, according to the company, laying the...
Benzinga  Jul 17  Comment 
A total of thirteen small-cap stocks registered gains of more than 10 percent on Tuesday. These names were helped, in part, by a rally in the stock market after a sharp morning decline. Stocks plunged at the open but recovered off of session lows...
StreetInsider.com  Jul 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Spectrum+Pharma+%28SPPI%29+Extends+Tender+for+Allos+Therapeutics+%28ALTH%29+/7565862.html for the full story.




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Allos Therapeutics Inc. (Allos) is a biopharmaceutical company focused on developing and commercializing small molecule drugs for the treatment of cancer. The company strives to develop proprietary products that have the potential to improve the standard of care in cancer therapy. Allos' goal is to build a profitable company by generating income from products it develops and commercializes, either alone or with one or more potential strategic partners. The company's focus is on product opportunities that leverage its internal clinical development and regulatory expertise and address important markets with unmet medical need. Allos may also seek to grow its existing portfolio of product candidates through product acquisition and in-licensing efforts.

Allos has two product candidates that are currently under clinical development, PDX (pralatrexate) and RH1.

Candidate


Target Indications


Status


PDX:






Chemotherapy


Peripheral T-cell lymphoma


Phase II ongoing




Non-Hodgkin's lymphoma and Hodgkin's disease


Phase I/II ongoing




cutaneous T-cell lymphoma


Phase I/II ongoing




Stage IIIB/IV non small cell lung cancer


Phase I ongoing


RH1:






Chemotherapy


Solid Tumors


Phase I ongoing


Allos Therapeutics was incorporated in 1992 and is headquartered in Westminster, CO.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki